Newly developed transarterial chemoembolization material: CDDP-lipiodol suspension

Area of Science:

• Oncology
• Radiology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide.
• Transarterial chemoembolization (TACE) is a standard locoregional therapy for unresectable HCC.
• Developing effective and safe TACE materials is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of Cis-Diamminedichloroplatinum (CDDP)-lipiodol suspension (CLS) as a novel TACE material for HCC.
• To assess plasma concentrations of CDDP after TACE with CLS compared to intravenous administration.
• To determine the potential for reduced systemic toxicity with CLS-based TACE.

Main Methods:

• CLS was prepared by suspending CDDP in lipiodol.
• CLS was administered via transarterial injection into the proper hepatic artery or its branches in HCC patients.
• Plasma levels of total and filtrable CDDP were measured post-TACE.
• Anticancer effects and adverse complications were monitored.

Main Results:

• CLS demonstrated significant anticancer effects in patients with hepatocellular carcinoma.
• Plasma concentrations of CDDP were substantially lower following TACE with CLS compared to intravenous CDDP administration.
• No major adverse complications were observed, likely attributable to the reduced systemic exposure to CDDP.

Conclusions:

• Cis-Diamminedichloroplatinum (CDDP)-lipiodol suspension (CLS) is an effective and potentially safer TACE material for HCC.
• The localized delivery of CDDP via CLS results in lower systemic drug concentrations, minimizing toxicity.
• CLS represents a promising advancement in TACE therapy for liver cancer.